Human Genome Epidemiology Literature Finder
Records 1 - 30 (of 48 Records) |
Query Trace: Neoplasms and CD274[original query] |
---|
TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer. Therapeutic advances in medical oncology 2021 8 13 17588359211038477. Li Teng, Wang Han, Xu Jiachen, Li Chengcheng, Zhang Yudong, Wang Guoqiang, Liu Yutao, Cai Shangli, Fang Wenfeng, Li Junling, Wang Zhij |
Comprehensive Analysis of the Immune-Oncology Targets and Immune Infiltrates of N -Methyladenosine-Related Long Noncoding RNA Regulators in Breast Cancer. Frontiers in cell and developmental biology 2021 7 9 686675. Zhang Xiaoqiang, Shen Li, Cai Ruyu, Yu Xiafei, Yang Junzhe, Wu Xian, Zhu Yanhui, Liu Xiao |
Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas. Aging 2021 Jun 13 . Han Song, Wang Peng-Fei, Cai Hong-Qing, Wan Jing-Hai, Li Shou-Wei, Lin Ze-Huan, Yu Chun-Jiang, Yan Chang-Xia |
Identification of an immune checkpoint gene signature that accurately predicts prognosis and immunotherapy response in endometrial carcinoma. Aging 2021 6 13 (12): 16696-16712. Li Shaowen, Dong Chunli, Chen Jiayan, Gao Xiaocui, Xie Xiuying, Zhang X |
Six mutator-derived lncRNA signature of genome instability for predicting the clinical outcome of colon cancer. Journal of gastrointestinal oncology 2021 11 12 (5): 2157-2171. Chen Shujia, Li Xiaofei, Zhang Jiachen, Li Li, Wang Xueqiu, Zhu Yinghui, Guo Lianyi, Wang Jiw |
H2AFZ Is a Prognostic Biomarker Correlated to TP53 Mutation and Immune Infiltration in Hepatocellular Carcinoma. Frontiers in oncology 2021 11 11 701736. Dong Mingwei, Chen Jing, Deng Yiran, Zhang Danying, Dong Ling, Sun Dalo |
Genomic alterations associated with mutational signatures, DNA damage repair and chromatin remodeling pathways in cervical carcinoma. NPJ genomic medicine 2021 Oct 6 (1): 82. Halle Mari K, Sundaresan Aishwarya, Zhang Jianqing, Pedamallu Chandra Sekhar, Srinivasasainagendra Vinodh, Blair Jessica, Brooke Dewey, Bertelsen Bjørn I, Woie Kathrine, Shrestha Sadeep, Tiwari Hemant, Wong Yick Fu, Krakstad Camilla, Ojesina Akinyemi |
Programmed Death Ligand 2 Gene Polymorphisms Are Associated With Lung Adenocarcinoma Risk in Female Never-Smokers. Frontiers in oncology 2021 11 753788. Liang Sheng-Kai, Chien Li-Hsin, Chang Gee-Chen, Tsai Ying-Huang, Su Wu-Chou, Chen Yuh-Min, Huang Ming-Shyan, Lin Hsien-Chih, Fang Wen-Tsen, Hung Hsiao-Han, Jiang Shih-Sheng, Chen Chih-Yi, Chen Kuan-Yu, Chang I-Shou, Hsiung Chao A, Chen Chien-Jen, Yang Pan-Chyr, |
Identification of Metabolism-Related Gene-Based Subgroup in Prostate Cancer. Frontiers in oncology 2022 12 909066. Yu Guopeng, Liang Bo, Yin Keneng, Zhan Ming, Gu Xin, Wang Jiangyi, Song Shangqing, Liu Yushan, Yang Qing, Ji Tianhai, Xu B |
Clinical significance and immune landscape of KIR2DL4 and the senescence-based signature in cutaneous melanoma. Cancer science 2022 7 113 (11): 3947-3959. Mao Rui, Ren Zhengyun, Yang Fan, Yang Peng, Zhang Tongto |
A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy. Frontiers in oncology 2022 12 922342. Qin Wan, Zhao Ben, Wang Duanrui, Liu Jiamin, Zhou Yilu, Zhu Wenjun, Huang Yongbiao, Qiu Hong, Yuan Xiangl |
Clinicopathologic and genomic characteristics of mucinous gastric adenocarcinoma. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2022 5 25 (4): 697-711. Lee Jae Eun, Choi Yoon Young, An Ji Yeong, Kim Ki Tae, Shin Su-Jin, Cheong Jae- |
Treatment Response to Immunotherapy After Crizotinib Resistance in a Patient With Pulmonary Sarcomatoid Carcinoma Harboring MET Exon 14 Skipping Mutation: A Case Report. Clinical Medicine Insights. Oncology 2022 2 16 11795549211067185. Gu Ling, Wei Xiaoying, Zhang Zixiang, Heng W |
A novel senescence-related lncRNA signature that predicts prognosis and the tumor microenvironment in patients with lung adenocarcinoma. Frontiers in genetics 2022 11 13 951311. Fang Xueying, Huang Enmin, Xie Xiaopeng, Yang Kai, Wang Shuqian, Huang Xiaoqing, Song M |
Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels. Annals of hematology 2022 Oct . Lewandowski Krzysztof, Kandu?a Zuzanna, Gniot Micha?, Paczkowska Edyta, Nawrocka Paulina Maria, Wojtaszewska Marzena, Janowski Micha?, Mariak Magdalena, Handschuh Luiza, Kozlowski Pio |
Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer. Journal for immunotherapy of cancer 2022 1 10 (1): . Nishimura Kazuki, Nishio Kyosuke, Hirosuna Kensuke, Komura Kazumasa, Hayashi Takuo, Fukuokaya Wataru, Ura Ayako, Uchimoto Taizo, Nakamura Ko, Fukushima Tatsuo, Yano Yusuke, Takahashi Nobushige, Nakamori Keita, Kinoshita Shoko, Matsunaga Tomohisa, Tsutsumi Takeshi, Tsujino Takuya, Taniguchi Kohei, Tanaka Tomohito, Uehara Hirofumi, Takahara Kiyoshi, Inamoto Teruo, Hirose Yoshinobu, Kimura Takahiro, Egawa Shin, Azuma Haruhi |
LCK and CD3E Orchestrate the Tumor Microenvironment and Promote Immunotherapy Response and Survival of Muscle-Invasive Bladder Cancer Patients. Frontiers in cell and developmental biology 2022 1 9 748280. Zheng Xiaonan, Liao Xinyang, Nie Ling, Lin Tianhai, Xu Hang, Yang Lu, Shen Bairong, Qiu Shi, Ai Jianzhong, Wei Qia |
Machine learning-based identification of glycosyltransferase-related mRNAs for improving outcomes and the anti-tumor therapeutic response of gliomas. Frontiers in pharmacology 2023 9 14 1200795. Chunyu Zhang, Wei Zh |
Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer. Frontiers in oncology 2023 8 13 1235902. Sarah Sammons, Andrew Elliott, Romualdo Barroso-Sousa, Saranya Chumsri, Antoinette R Tan, George W Sledge, Sara M Tolaney, Evanthia T Roussos Torr |
Immunogenetic polymorphisms predict therapeutic efficacy and survival outcomes in tumor patients receiving PD-1/PD-L1 blockade. International immunopharmacology 2023 6 121 110469. Zhaodan Xin, Liting You, Jin Li, Feifei Na, Min Chen, Jiajia Song, Ling Bai, Hao Chen, Jianzhao Zhai, Xiaohan Zhou, Juan Zhou, Binwu Yi |
Development and validation of metabolic models for predicting survival and immune status of hepatocellular carcinoma patients. Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2023 5 . Xueying Li, Mengli Gu, Qiying Hu, Yihui Weng, Xianlei C |
Common inherited variants of PDCD1, CD274 and HAVCR2 genes differentially modulate the risk and prognosis of adenocarcinoma and squamous cell carcinoma. Journal of cancer research and clinical oncology 2023 2 . Moksud Nafeesa, Wagner Marta, Pawe?czyk Konrad, Por?bska Irena, Muszczy?ska-Bernhard Beata, Kowal Aneta, Wi?niewski Andrzej, Kosacka Monika, Ko?czak Julia, Karpi?ski Pawe?, Frydryk Dominik, Andrzejczak Anna, Karabon Lidia, Ku?nierczyk Piotr, Jasek Moni |
Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas. Frontiers in molecular biosciences 2023 2 10 963639. Huang Wei, Wu Yuliang, Zhu Jihui, Luo Ning, Wang Chunyan, Liu Shupeng, Cheng Zhongpi |
ROS1 as a possible prognostic biomarker of cervical adenocarcinoma: An exploratory analysis with next-generation sequencing. Gynecologic oncology 2023 2 171 59-66. Machida Hiroko, Matsuo Koji, Tanaka Masayuki, Kitatani Kanae, Takase Akinori, Yokoyama Keiko, Kajiwara Hiroshi, Yasaka Miwa, Ikeda Masae, Yoshida Hiroshi, Hirasawa Takeshi, Mikami Mik |
Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer. Scientific reports 2023 12 13 (1): 21816. Xiaoxu Chen, Zheng Qin, Xiao Zhu, Lili Wang, Changying Li, Haitao Wa |
Identification of molecular subtypes and a risk model based on inflammation-related genes in patients with low grade glioma. Heliyon 2023 12 9 (12): e22429. Cheng Long, Ya Song, Yimin Pan, Changwu |
Transcriptional analysis of landmark molecular pathways in lung adenocarcinoma results in a clinically relevant classification with potential therapeutic implications. Molecular oncology 2023 11 . Sara Hijazo-Pechero, Ania Alay, David Cordero, Raúl Marín, Noelia Vilariño, Ramón Palmero, Jesús Brenes, Aina Montalban-Casafont, Ernest Nadal, Xavier So |
The blockage signal for PD-L1/CD274 gene variants and their potential impact on lung carcinoma susceptibility. International immunopharmacology 2023 11 125 (Pt A): 111180. Mohamed I Sakran, Adel I Alalawy, Amnah A Alharbi, Mohamed E El-Hefnawy, Salem M Alzahrani, Ahmed Alfuraydi, Fahad Mohammed Alzuaibr, Nahla S Zidan, Afaf M Elsaid, Eman A Toraih, Rami M Elshaz |
Non-invasive plasma testing for CD274 UTR structural variations by next-generation sequencing in cancer. Cell death discovery 2023 1 9 (1): 35. Zhang Wenjuan, Cao Jian, Liu Ke, Qu Ziwei, Zheng Ying, Yu Jun, Yu Yishan, Wang Yongsheng, Wu Wen |
Polymorphisms of the PD-L1 gene 3'-untranslated region are associated with the expression of PD-L1 in non-small cell lung cancer. Genes, chromosomes & cancer 2024 1 63 (1): e23216. Yoshihito Ohhara, Utano Tomaru, Ichiro Kinoshita, Kanako C Hatanaka, Takuro Noguchi, Yutaka Hatanaka, Toraji Amono, Yoshihiro Matsuno, Hirotoshi Dosaka-Aki |
- Page last reviewed:Feb 1, 2024
- Page last updated:Mar 25, 2024
- Content source: